多西紫杉醇联合米托蒽醌治疗晚期乳腺癌

Clinical trial of docetaxel combined with mitoxanfrone for advanced breast cancer

目的:评定多的紫杉醇联合米托蒽醌治疗晚期乳腺癌临床疗效及不良反应。方法:52例病人均有病理学诊断及可评价客观指标。采用多西紫杉醇75mg/m^2d1,静脉滴注1小时,用多西紫杉醇前1天口服地塞米松10mg,连续3天。米托蒽酿14mg/m^2d1化疗。21～30天为1周期,2周期评价疗效。结果:52例病人可评价疗效和不良反应。CR 6例,PR 32例,NC 10例,PD 4例,有效率73.08％,不良反应主要为白细胞减少Ⅲ度占32.69％,Ⅳ度占25.00％;脱发Ⅱ度占44.23％,Ⅲ度占21.15％;腹泻Ⅱ度占32.69％,Ⅲ度占21.15％。结论:多西紫杉醇联合米托蒽醌治疗晚期乳腺癌有效率较高,不良反应可以耐受。

Objective:To evaluate the curative effect and toxieity of docetaxel plus mitoxantrone in the treatment of advanced breast cancer. Methods: Fifty-two pathologically and cytologically proved cases of breast cancer were treated with intravenous infusion of docetaxel 75mg/m2 on the first day,and oral dexamethasone 10mg was given on the day before docetaxel therapy and it was continued for three days. Mitoxantrone was treated with intravenous infusion of Mitoxantrone 14mg/m2- on the first day. Each cycle was 21 to 30 days and the clinical response was assessed after two cycles. Results: It showed that CR 6, PR 32, NC 10, PD 4 cases with an overall effective rate of 73. 08% . The main side effects included neutropenia: grade Ⅲ 32.69% , grade Ⅳ 25.00% respectively, alopecia: grade Ⅱ 44.23% ,grade Ⅲ 21. 15%. Diarrhea: grade Ⅱ 32.69% .grade Ⅲ 21. 15%. Conclusion: Docetaxel plus Mitoxantrone is effective for advanced breast cancer and toxieities are well tolerated.